BioCentury
ARTICLE | Company News

Alnylam, Arrowhead deal

January 16, 2012 8:00 AM UTC

Alnylam granted Arrowhead an exclusive, worldwide license to IP covering an RNAi therapeutic to treat HBV infection. Alnylam is eligible for milestones and royalties. Additionally, Arrowhead granted A...